|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | ONE JOHNSON & JOHNSON PLAZA |
Address2 | |
City | NEW BRUNSWICK |
State | NJ |
Zip Code | 08933 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 20686-12
|
||||||||
|
6. House ID# 303480000
|
TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Clifford Holland, Corporate Vice President, Government Affairs and Policy |
Date | 01/22/2013 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
- Issues related to dextromethorphan
- Issues related to Pseudoephedrine
- Issues related to the regulation of Cosmetic Products.
- HR 2359, "Safe Cosmetics Act of 2011", regarding all provisions.
- HR 4395, "Cosmetic Safety Amendments Act of 2012", regarding all provisions.
- HR 4262, "Cosmetic Safety Enhancement Act of 2012", regarding all provisions.
- S 3376, "Prevent Abuse of Cough Treatment Act of 2012", regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darrel |
Jodrey |
|
|
|
Gregory |
Aronin |
|
|
|
Don |
Bohn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
- Issues related to chemicals in the environment
- Issues related to the Toxic Substances Control Act
- S. 847, "Safe Chemicals Act of 2011", regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darrel |
Jodrey |
|
|
|
Gregory |
Aronin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
- Issues related to ensuring quality of supply chain for FDA regulated products.
- Issues related to Accountable Care Organizations.
- Issues related to Physician Payment Sunshine provisions.
- Issues related to the "Regulation & Reimbursement of Diagnostics", regarding all provisions.
- Implementation of the Health Care Reform Bill, regarding Medicare wellness benefit.
- Issues related to maintaining the biosimilars statute without changes.
- HR 2960, "National Diabetes Clinical Care Commission Act", regarding all provisions.
- HR 3026, "Safeguarding America's Pharmaceutical Act of 2011", regarding all provisions.
- Prescription Drug User Fee Act, regarding all provisions
- Personalized Medicine Incentives and Regulation.
- Issues related to Alzheimer's research.
- HR 2939, "Pharmaceutical Stewardship Act of 2011", regarding all provisions.
- HR 3497, "MODERN Cures Act of 2011", regarding all provisions.
- HR 3207, "Modernizing Laboratory Test Standards for Patients Act of 2011", regarding all provisions.
- S 1700, "Medical Device Regulatory Improvement Act", regarding all provisions.
- S 1865, "Patient Access to Medical Innovation Act", regarding all provisions.
- S 1995, "Medical Device Patient Safety Act", regarding all provisions.
- Issues related to vision care coverage under PPACA.
- Medical Device User Fee Act Reauthorization.
- HR 1483, "The Drug Safety Enhancement Act of 2011", regarding all provisions.
- HR 3847, "Safety of Untested and New Devices Act of 2012", regarding all provisions.
- HR 3975, "A bill to extend provisions of the Pediatric Medical Device Safety and Improvement Act of 2007", regarding all provisions.
- S 2113, "A bill to empower the Food and Drug Administration to ensure a clear and effective pathway that will encourage innovative products to benefit patients and improve public health." regarding all provisions.
- S 2193, "Ensuring Safe Medical Devices for Patients", regarding all provisions.
- HR 5, "Protecting Access to Healthcare (PATH) Act", regarding all provisions.
- HR 452, "Medicare Decisions Accountability Act of 2011", regarding all provisions.
- Issues related to the repeal and/or reform of Independent Payment Advisory Boards.
- HR 5937, "Breast Cancer Patient Education Act of 2012", regarding all provisions.
- HR 5998, "USPSTF Transparency and Accountability Act of 2012", regarding all provisions.
- S 3187, "Food and Drug Administration Safety and Innovation Act", regarding all provisions.
- S 2516, "Food and Drug Administration Safety and Innovation Act", regarding all provisions.
- HR 6584, Verifying Authority and Legality In Drug Compounding Act of 2012, regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darrel |
Jodrey |
|
|
|
Mark |
Reese |
|
|
|
Brian |
Burns |
|
|
|
Jane |
Adams |
|
|
|
Charles |
Nau |
|
|
|
Lauryl |
Jackson |
|
|
|
Julie |
Cohen |
|
|
|
Don |
Bohn |
|
|
|
Gregory |
Aronin |
|
|
|
Kimberly |
Davis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
- HR 905/ S 733, "To Amend Part B or Title XVIII of the Social Security Act to exclude customary prompt pay discounts from Manufacturers to Wholesalers from the average sales price for drugs & biologicals under Medicare", regarding all provisions.
- HR 1041, "The Fairness in Medicare Bidding Act", regarding all provisions.
- Issues related to Medicare reimbursement for Clinical Laboratory Services.
- HR 1041, "Fairness in Medicare Bidding Act", regarding all provisions.
- Medicare Part D Letter
- HR 452, "Medicare Decisions Accountability Act of 2011", regarding all provisions.
- S 668, "Health Care Bureaucrats Elimination Act", regarding all provisions.
- Issues related to Physician-owned Companies that manufacture or distribute medical devices.
- S 1468/ HR 2787, "Medicare Diabetes Self-Management Training Act of 2011", regarding all provisions.
- PL 112-96, "Middle Class Tax Relief and Job Creation Act of 2012", provisions regarding Medicare clinical laboratory services.
- Issues related to implantable medical devices.
- HR 5998, "USPSTF Transparency and Accountability Act of 2012", regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lauryl |
Jackson |
|
|
|
Mark |
Reese |
|
|
|
Julie |
Cohen |
|
|
|
Kimberly |
Davis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
- Issues regarding tax reform.
- HR 605, "The Patients' Freedom to Choose Act", regarding all provisions.
- HR 436, "Protect Medical Innovation Act of 2011", regarding all provisions.
- HR 488, "Save Our Medical Devices Act of 2011", regarding all provisions.
- HR 734, "To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes", regarding all provisions.
- S 17, "Medical Device Access and Innovation Protection Act", regarding all provisions.
- S 262, "A bill to repeal the excise tax on medical device manufacturers", regarding all provisions.
- HR 942, "American Research and Competitiveness Act of 2011", regarding all provisions
- Issues related to tax legislation.
- Issues related to the President's proposed "Job Bill" (2011)
- S 1368/ HR 2529, "Restoring Access to Medication Act", regarding all provisions.
- S 1584, "Drug Safety and Accountability Act of 2011", regarding all provisions.
- HR 2245, "Preserving Access to Life-Saving Medication Act", regarding all provisions.
- Issues related to Ways and Means tax reform discussion draft.
- HR 2735, "To amend the Internal Revenue Code of 1986 to make permanent the look-through treatment of payments between related controlled foreign corporations", regarding all provisions.
- S 1577, "Greater Research Opportunities With Tax Help Act", regarding all provisions.
- PL 112-96, "Middle Class Tax Relief and Job Creation Act of 2012", provisions regarding Medicare clinical laboratory services.
- HR 1864, "Mobile Workforce State Income Tax Simplification Act of 2011", regarding all provisions.
- S 2091, "United States Job Creation and International Tax Reform Act of 2012", regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Don |
Bohn |
|
|
|
Jane |
Adams |
|
|
|
Darrel |
Jodrey |
|
|
|
Brian |
Burns |
|
|
|
David |
Kavanaugh |
|
|
|
Julie |
Cohen |
|
|
|
Kimberly |
Davis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
- HR 5, "Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011", regarding all provisions.
- HR 675, "Strengthening Medicare Anti-Fraud Measures Act of 2011", regarding all provisions.
- Issues regarding Health Courts
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gregory |
Aronin |
|
|
|
Brian |
Burns |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LAW
16. Specific lobbying issues
- Issues regarding the theft of medical products.
- S 1002, "SAFE DOSES Act", regarding all provisions.
- HR 4223, "Safe Doses Act", regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Reese |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
- Korea-US Free Trade Agreement
- Issues related to current and future trade negotiations.
- TransPacific Partnership trade negotiations.
- Pending legislation regarding the extension of permanent normal trade relations to Russia.
17. House(s) of Congress and Federal agencies Check if None
U.S. Trade Representative (USTR), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Kavanaugh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
- Issues related to ADAP funding.
- Issues related to FDA funding.
- Issues related to Alzheimer's funding.
- Issues related to deficit reductions/ fiscal cliff
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Nau |
|
|
|
Julie |
Cohen |
|
|
|
Brian |
Burns |
|
|
|
Darrel |
Jodrey |
|
|
|
Mark |
Reese |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FIN
16. Specific lobbying issues
- HR 1062, "The Burdensome Data Collection Relief Act", regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Kavanaugh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |